Peter Virsik
Chief Operating Officer bij ESSA PHARMA INC.
Vermogen: 101 371 $ op 31-03-2024
Profiel
Peter A.
Virsik is currently the Chief Operating Officer & Executive Vice President at ESSA Pharma, Inc. He previously worked as an Associate Director at Gilead Sciences, Inc. from 2000 to 2005 and as the Senior Vice President-Corporate Development at XenoPort, Inc. from 2005 to 2015.
Virsik received his undergraduate degree from the University of California, Berkeley, his graduate degree from the University of Michigan, and his MBA from Kellogg School of Management.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ESSA PHARMA INC
0.03% | 05-04-2024 | 11 940 ( 0.03% ) | 101 371 $ | 31-03-2024 |
Actieve functies van Peter Virsik
Bedrijven | Functie | Begin |
---|---|---|
ESSA PHARMA INC. | Chief Operating Officer | 01-08-2016 |
Eerdere bekende functies van Peter Virsik
Bedrijven | Functie | Einde |
---|---|---|
XENOPORT, INC. | Corporate Officer/Principal | 01-01-2015 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-01-2005 |
Opleiding van Peter Virsik
University of California, Berkeley | Undergraduate Degree |
University of Michigan | Graduate Degree |
Kellogg School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ESSA PHARMA INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
XenoPort, Inc.
XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |